Alverno Labs To Implement Artificial Intelligence For Pathology
Alverno Laboratories (Hammond, IN), which transitioned to digital pathology in 2019 when it implemented Philips IntelliSite Pathology Solution, now says it will add artificial intelligence to aid its pathologists in cancer diagnosis. Alverno will use the Galen AI system developed by Ibex
Medical Analytics (Tel Aviv, Israel). Ibex’s Galen platform recently received the Breakthrough Device Designation from FDA, which will help fast track the clinical review and clearance process, and is CE marked in Europe for
breast and prostate cancer. Alverno is an independent lab owned by Franciscan Alliance and AMITA Health. Alverno manages a core lab and 32 hospital labs in Indiana and Illinois. It consults on 150,000 histological cases per year, which translates to more than 1.1 million tissue slides.